Bioextrax AB (SE:BIOEX)
:BIOEX
Want to see SE:BIOEX full AI Analyst Report?
BIOEX Stock Chart & Stats
kr3.19
kr0.10(3.70%)
At close: 4:00 PM EST
kr3.19
kr0.10(3.70%)
Day’s Range― - ―
52-Week Rangekr1.60 - kr3.98
Previous CloseN/A
Volume15.49K
Average Volume (3M)82.14K
Market Cap
kr115.67M
Enterprise Valuekr87.92M
Total Cash (Recent Filing)kr3.93M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 21, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding47,601,730
10 Day Avg. Volume104,394
30 Day Avg. Volume82,137
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)kr2.34M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt balance sheet materially reduces refinancing and interest-rate risk, giving management optionality to pursue commercialization or partner-funded projects without near-term debt service. This durable financial flexibility lengthens runway versus leveraged peers while external funding is sought.
Industrial Biotech / Biorefinery FocusOperating in industrial bioprocessing and biorefinery aligns with long-term structural trends toward circular economy, sustainable ingredients, and side-stream valorization. These market tailwinds support multi-year demand growth for bio-based inputs and create enduring commercial opportunities if processes are scalable.
Diverse Commercialization PathwaysMultiple monetization routes—direct product sales, licensing IP, and fee-for-service development—provide durable strategic flexibility. Licensing and services can scale with lower capital intensity than in-house manufacturing, enabling revenue growth and margin improvement once technologies prove industrially viable.
Bears Say
Persistent Negative ProfitabilityStructural negative gross margins show core processes currently costlier than revenues, implying the business lacks operating leverage at present. Without sustained gross-margin improvement or higher volumes, losses will continue, eroding equity and undermining long-term sustainability of operations.
Chronic Cash BurnPersistent negative operating and free cash flow—worsening in 2025—indicates the business is not self-funding and will likely need external capital to continue. Repeated funding rounds risk shareholder dilution, constrain investment in scale-up, and create execution risk over the coming months.
Very Small, Declining Revenue BaseA tiny, volatile revenue base with recent year-over-year declines signals limited commercial traction and weak product-market fit. Low sales volumes prevent absorption of fixed costs, delay margin expansion, and elevate the probability that continued losses will deplete capital unless growth resumes.
BIOEX FAQ
What was Bioextrax AB’s price range in the past 12 months?
Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.
What is Bioextrax AB’s market cap?
Bioextrax AB’s market cap is kr115.67M.
When is Bioextrax AB’s upcoming earnings report date?
Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 68 days.
How were Bioextrax AB’s earnings last quarter?
Bioextrax AB released its earnings results on May 20, 2026. The company reported -kr0.09 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.01.
Is Bioextrax AB overvalued?
According to Wall Street analysts Bioextrax AB’s price is currently Overvalued.
Does Bioextrax AB pay dividends?
Bioextrax AB does not currently pay dividends.
What is Bioextrax AB’s EPS estimate?
Bioextrax AB’s EPS estimate is -0.09.
How many shares outstanding does Bioextrax AB have?
Bioextrax AB has 47,601,730 shares outstanding.
What happened to Bioextrax AB’s price movement after its last earnings report?
Bioextrax AB reported an EPS of -kr0.09 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 11.2%.
Which hedge fund is a major shareholder of Bioextrax AB?
Currently, no hedge funds are holding shares in SE:BIOEX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioextrax AB
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.
Technical Analysis
Scandinavian Enviro Systems AB
―
Axolot Solutions Holding AB
―
Nordic LEVEL Group AB Class B
―
CirChem AB
―
Clemondo Group AB
―